We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
PanCD44 Immunohistochemical Evaluation in Prostatectomies from Patients with Adenocarcinoma.
- Authors
Hirth, Carlos Gustavo; Santos, Adriele Machado dos; Cerqueira, João Batista Gadelha de; Jamacaru, Francisco Vagnaldo Fechine; Cunha, Maria do Perpétuo Socorro Saldanha da; Dornelas, Conceição Aparecida
- Abstract
<italic>Introduction</italic>. CD44 has been proposed as a prognostic marker and a stem cell marker but studies in patients with prostate cancer have yielded inconsistent results.<italic> Patients and Methods</italic>. Patients submitted to radical prostatectomy between 2008 and 2013 at a university hospital were followed with biannual serum PSA tests to determine the biochemical recurrence (BR). Archived paraffin blocks with neoplastic and nonneoplastic tissue were evaluated immunohistochemically for a panCD44 and MYC.<italic> Results</italic>. Sixty-nine patients completed follow-up and were included. CD44 positivity was observed in inflammatory cells (42%), nonneoplastic epithelium (39.7%), and neoplastic tissue (12.3%). In nonneoplastic tissues staining was observed in basal and luminal cells with the morphology of terminally differentiated cells. In neoplastic tissues, CD44 negativity was correlated with higher Gleason scores (Rho = −0.204; p=0.042) and higher preoperative serum PSA levels when evaluated continuously (p=0.029). CD44 expression was not associated with tumor stage (p=0.668), surgical margin status (p=0.471), or BR (p=0.346), nor was there any association between CD44 and MYC expression in neoplastic tissue (p=1.0).<italic> Conclusion</italic>. In the bulk of cells, the minority of cancer stem cells would not be detected by immunohistochemistry using panCD44. As a prognostic marker, its expression was weakly correlated with Gleason score and preoperative PSA level, but not with surgical margin status, tumor stage, or BR.
- Subjects
ACADEMIC medical centers; ADENOCARCINOMA; ANTIGENS; BIOMARKERS; CANCER relapse; CANCER cells; EPITHELIAL cells; GENE expression; PATIENT aftercare; IMMUNOHISTOCHEMISTRY; INFLAMMATION; ONCOGENES; PARAFFIN wax; PROSTATE tumors; PROSTATECTOMY; STAINS &; staining (Microscopy); PROSTATE-specific antigen; PREOPERATIVE period; TUMOR grading; PROGNOSIS
- Publication
BioMed Research International, 2018, Vol 2018, p1
- ISSN
2314-6133
- Publication type
Article
- DOI
10.1155/2018/2061268